This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Microdialysis and Pharmacokinetic Study of TR-701

This study has been completed.
Information provided by (Responsible Party):
Trius Therapeutics LLC Identifier:
First received: April 23, 2008
Last updated: April 27, 2016
Last verified: April 2016
The purpose of this study is to measure the penetration of TR-700 into subcutaneous adipose tissue and skeletal muscle after a single oral dose of 600 mg TR-701

Condition Intervention Phase
Healthy Drug: TR-700 (active moiety) Drug: TR-701 (pro-drug) Phase 1

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Basic Science
Official Title: An Open Label, Single Dose, Microdialysis and Pharmacokinetic Study of TR-701 in Normal Healthy Adults

Resource links provided by NLM:

Further study details as provided by Trius Therapeutics LLC:

Primary Outcome Measures:
  • Subcutaneous tissue concentrations of TR-700 [ Time Frame: Single day ]

Enrollment: 15
Study Start Date: April 2008
Study Completion Date: March 2009
Primary Completion Date: June 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Pilot study
3 subjects, open lable, microdialysis single dose.
Drug: TR-700 (active moiety)
A TR-700 solution will be locally administered via a microdialysis probe into the skeletal muscle and subcutanous tissue (just under the skin) at a concentration of approximately 2 µg/mL at a flow rate of 1.5 µL/min for 60 minutes for a total maximum dose of 0.36 µg (0.18 µg per probe).
Experimental: Main Study
12 subjects, open label, single dose of 600 mg.
Drug: TR-701 (pro-drug)
Each subject enrolled in the Main study will receive a single oral dose of 600mg TR-701

Detailed Description:
This study will be conducted in two parts: a Pilot Study and a Main Study. The Pilot Study will be conducted to assess recovery of exogenously administered TR-700 (microbiologically active moiety) via microdialysis. In the Main Study, pharmacokinetics of TR-700 will be determined in both soft tissues (via microdialysis) and plasma after a single oral dose of 600 mg TR-701 (prodrug).

Ages Eligible for Study:   18 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • Body mass index of 20 to 29 kg/m2
  • Agree not to consume any products containing tobacco, alcohol, quinine, grapefruit, caffeine, or high levels of tyramine
  • Agree not to use any other medication
  • Female subjects must be postmenopausal (for at least 6 months), surgically sterile, abstinent, or, if sexually active, be practicing an effective method of birth control

Exclusion Criteria:

  • History of gastric or duodenal ulcer within 1 year before enrollment
  • Has known or suspected hypersensitivity or intolerance to heparin, if an indwelling cannula (e.g., heparin lock) is used
  • Recent febrile illness (less than 72 hours before the first intake of study medication).
  • Significant blood loss (300 mL) or donation of blood within the 60 days before the Screening visit
  • Women who are pregnant or breast-feeding
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00666601

United States, Florida
General Clinical Research Center
Gainesville, Florida, United States, 32604
Sponsors and Collaborators
Trius Therapeutics LLC
Principal Investigator: Harmut Derendorf, PhD University of Florida
  More Information

Responsible Party: Trius Therapeutics LLC Identifier: NCT00666601     History of Changes
Other Study ID Numbers: 1986-022
TR701-102 ( Other Identifier: TrisuRX Unique ID )
Study First Received: April 23, 2008
Last Updated: April 27, 2016

Keywords provided by Trius Therapeutics LLC:
Healthy subjects

Additional relevant MeSH terms:
Torezolid phosphate
Anti-Bacterial Agents
Anti-Infective Agents processed this record on August 18, 2017